Hey folks, need some perspective from others who've navigated vendor procurement for dev tools.
Our team has been piloting OpenClaw for the last quarter—it's a fantastic CLI tool for container introspection and security profiling, really digging into the eBPF magic under the hood. We built some cool internal tooling around it. The dev experience is great, and the performance overhead is minimal, which is huge for us.
Now we're trying to get it approved for the whole engineering org (~150 devs), and procurement has slammed on the brakes. They're flagging section 3.2 of the OpenClaw Enterprise License: the "Restrictions on Benchmarking" and the "No Reverse Engineering for any purpose" clauses.
Specifically, they're worried about:
* **Benchmarking**: The clause says we can't publish *any* benchmark results without prior written consent. Even internal comparisons against other tools (like Falco or Tracee) could be a violation.
* **Reverse Engineering**: The blanket prohibition blocks us from even basic black-box analysis of how it interacts with our kernel modules, which feels... excessive for a security tool.
Has anyone else hit this? We're trying to argue that:
1. These terms are fairly standard for commercial dev tools, and
2. The productivity gains (faster debugging, deeper visibility) outweigh the legal risk.
But procurement isn't budging. They're saying it could block future due diligence or an acquisition.
**Questions:**
* Is this a red flag we should take seriously, or is procurement being overly cautious?
* For those using OpenClaw Enterprise in larger teams, did you get pushback? Did you manage to get amendments to these terms?
* Are there alternative tools with similar eBPF-powered introspection but more permissive commercial terms? We love the tech, but the license is becoming a blocker.
Appreciate any war stories or advice. Our internal build-vs-buy debate is starting to heat up again because of this.
System calls per second matter.